OncoMatch/Clinical Trials/NCT02106988
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
Is NCT02106988 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lymphoma.
Treatment: Dexamethasone · Etoposide phosphate · Ifosfamide · Mesna · Carboplatin — The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this study. All will be enrolled at MD Anderson.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Disease stage
Required: Stage I, II
Prior therapy
Cannot have received: radiation therapy
Exception: if re-treatment would lead to violation of known radiation dose tolerance limits for that site
Prior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that site.
Lab requirements
Blood counts
ANC > 1000 at baseline, or willingness to accept supportive measures such as transfusions, filgrastim, and Epoetin
Kidney function
serum creatinine ≤ 2.0 mg/dL within two weeks before protocol entry
Liver function
Bilirubin ≤ 1.5x ULN; ALT ≤ 2x ULN; AST ≤ 2x ULN; values within two weeks before protocol entry
Cardiac function
Left ventricular ejection fraction ≥ 50% by nuclear medicine scan or echocardiography
Adequate blood cell counts (i.e. ANC > 1000) at baseline, or willingness to accept supportive measures such as transfusions, filgrastim, and Epoetin. Adequate liver function as indicated by: Bilirubin ≤ 1.5x ULN, ALT ≤ 2x ULN or AST ≤ 2x ULN, values within two weeks before protocol entry. Serum creatinine ≤ 2.0 mg/dL within two weeks before protocol entry. Left ventricular ejection fraction ≥ 50% by nuclear medicine scan or echocardiography.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify